Medicine:ImmunityBio COVID-19 vaccine
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector[1] COVID-19 vaccine developed by the United States-based ImmunityBio.[2][1]
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | viral |
| Clinical data | |
| Trade names | hAd5 |
Manufacturing
The BioVac Institute, a state-backed South Africa n vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with United States based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa [3]
ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.[4][5]
History
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[6]
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials.[7] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[7]
Clinical trials
ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa .[3][8][9][needs update]
References
- ↑ 1.0 1.1 "ImmunityBio Inc: hAd5-Covid-19 – COVID19 Vaccine Tracker". https://covid19.trackvaccines.org/vaccines/49/.
- ↑ "SA's Biovac to team up with US based ImmunityBio in making its vaccine". https://www.businessinsider.co.za/sas-biovac-to-team-up-with-us-based-immunitybio-in-making-its-vaccine-2021-3.
- ↑ 3.0 3.1 "Covid-19 to Serve as Platform for South African Vaccine Industry" (in en). Bloomberg.com. 2021-03-19. https://www.bloomberg.com/news/articles/2021-03-19/immunitybio-to-have-covid-19-vaccine-made-in-south-africa.
- ↑ "Nzimande excited about vaccine partnership between Biovac & ImmunityBio" (in en). https://ewn.co.za/2021/03/18/nzimande-announces-manufacturing-partnership-between-sa-s-biovac-and-us-firm-immunitybio.
- ↑ "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says" (in en-US). https://www.news24.com/fin24/companies/health/sas-biovac-to-use-deal-with-us-based-immunitybio-to-boost-local-vaccine-creation-ceo-says-20210320.
- ↑ "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News 98 (19). 12 May 2020. https://cen.acs.org/pharmaceuticals/vaccines/Adenoviral-vectors-new-COVID-19/98/i19.
- ↑ 7.0 7.1 "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". Science (magazine). American Association for the Advancement of Science. 1 June 2020. https://www.science.org/content/article/operation-warp-speed-selects-billionaire-scientist-s-covid-19-vaccine-monkey-tests.
- ↑ "ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread" (in en). 2021-01-19. https://www.businesswire.com/news/home/20210119005426/en/%C2%A0ImmunityBio-Announces-Phase-I-Trial-of-COVID-19-Vaccine-Candidate-in-South-Africa-as-New-Variants-of-SARS-CoV-2-Spread.
- ↑ "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says" (in en-US). https://www.news24.com/fin24/Companies/Health/sas-biovac-to-use-deal-with-us-based-immunitybio-to-boost-local-vaccine-creation-ceo-says-20210320.
External links
 |
